Drug Trial Radar · NCT03340597
Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Aug 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Dec 12, 2017
Primary completion
Apr 13, 2018
Study completion Apr 13, 2018
Sponsor
- Lead sponsor
- F2G LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Covance
- First posted
- Nov 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase I, open label study evaluating safety, tolerability and pharmacokinetics of F901318 in healthy subjects following up to 28 days dosing, where F901318 is given orally . The effect of food upon the pharmacokinetics of F901318 and the effect of F901318 upon the pharmacokinetics of midazolam will also be assessed.
Conditions
- Invasive Aspergillosis
Interventions
F901318Drug
F901318 tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent adverse eventsTime frame: 18 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance Clinical Research Unit
Leeds, West Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.